跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 41 条关于
“KAT7”
全部
41
临床试验
8
药物
21
机构
2
资讯
10
9个月前
IDEAYA Biosciences Submits IND for First-in-Class KAT6/7 Dual Inhibitor IDE574 Targeting Breast and Lung Cancers
去年
IDEAYA Advances Oncology Pipeline with Novel Inhibitors and Gilead Collaboration
去年
Closed Loop Medicine Appoints Kate Woolland as CEO to Drive Precision Dosing Commercialization
去年
Olema's KAT6 Inhibitor OP-3136 Shows Promising Anti-Tumor Activity Across Multiple Cancer Types
29天前
EverGlade Adds Former ARPA-H Scientific Advisor Kate Teffer to Expand Federal Health Research Capabilities
去年
Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients: KAT-AKI Trial
去年
Olema Oncology's KAT6 Inhibitor OP-3136 Receives FDA IND Clearance, Phase 1 Trial Planned for 2025
去年
Pfizer Advances Australian-Discovered KAT6 Inhibitor PF-07248144 to Phase 3 Trial for HR+/HER2- Metastatic Breast Cancer
11个月前
Kynexis Initiates Phase 2 Trial of First-in-Class KAT-II Inhibitor for Schizophrenia-Associated Cognitive Impairment
上个月
Kynexis Extends Series A to €97 Million to Advance First-in-Class KAT-II Inhibitor for Cognitive Impairment in Schizophrenia